PriceTargets.com logo

Iovance Biotherapeutics - IOVA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $20.25
  • Forecasted Upside: 463.28%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$3.60 As of 03/14/2025 04:29 PM ET
▲ +0.075 (2.13%)

This chart shows the closing price for IOVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$3.52Closing price on 03/13/25:
Get New Iovance Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IOVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IOVA

Analyst Price Target is $20.25
▲ +463.28% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $20.25, with a high forecast of $32.00 and a low forecast of $6.00. The average price target represents a 463.28% upside from the last price of $3.60.

This chart shows the closing price for IOVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/253/26$2.46$9.85$17$25$32Closing price on 03/13/25: $3.52High$32.00Average$20.25Low$6.00




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Iovance Biotherapeutics. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/3/2025Truist FinancialLower TargetBuy ➝ Buy$25.00 ➝ $15.00
3/3/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$22.00 ➝ $19.00
3/3/2025Chardan CapitalLower TargetBuy ➝ Buy$34.00 ➝ $30.00
2/28/2025Robert W. BairdLower TargetOutperform ➝ Outperform$24.00 ➝ $20.00
2/28/2025Piper SandlerLower TargetNeutral ➝ Neutral$7.50 ➝ $6.00
2/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
1/31/2025Piper SandlerLower TargetNeutral ➝ Neutral$10.00 ➝ $7.50
11/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
10/24/2024UBS GroupInitiated CoverageBuy$17.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
7/29/2024Piper SandlerDowngradeOverweight ➝ Neutral$19.00 ➝ $10.00
6/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
6/20/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $23.00
5/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
3/14/2024Piper SandlerBoost TargetOverweight ➝ Overweight$18.00 ➝ $19.00
3/1/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$22.00 ➝ $25.00
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
2/29/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$19.00 ➝ $21.00
2/29/2024BarclaysBoost TargetOverweight ➝ Overweight$18.00 ➝ $22.00
2/20/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $25.00
2/20/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$17.00 ➝ $22.00
2/20/2024Piper SandlerBoost TargetOverweight ➝ Overweight$14.00 ➝ $18.00
2/20/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$13.00 ➝ $19.00
2/20/2024Chardan CapitalBoost TargetBuy ➝ Buy$29.00 ➝ $34.00
12/27/2023HC WainwrightLower TargetBuy ➝ Buy$38.00 ➝ $28.00
12/27/2023Truist FinancialReiterated RatingBuy ➝ Buy$17.00
11/20/2023The Goldman Sachs GroupInitiated CoverageBuy$12.00
11/7/2023HC WainwrightLower TargetBuy ➝ Buy$38.00 ➝ $28.00
9/18/2023BarclaysLower TargetOverweight ➝ Overweight$40.00 ➝ $18.00
9/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$38.00
9/15/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$18.00
9/15/2023MizuhoReiterated RatingBuy ➝ Buy$30.00
9/15/2023Truist FinancialReiterated RatingBuy ➝ Buy$17.00
9/13/2023Stifel NicolausLower TargetBuy ➝ Buy$27.00 ➝ $26.00
8/17/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$18.00
8/16/2023Chardan CapitalReiterated RatingBuy ➝ Buy$29.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$38.00
8/9/2023Chardan CapitalReiterated RatingBuy ➝ Buy$29.00
8/9/2023Robert W. BairdLower Target$23.00 ➝ $20.00
5/30/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$11.00 ➝ $17.00
5/30/2023Stifel NicolausBoost Target$21.00 ➝ $24.00
5/23/2023Robert W. BairdBoost Target$20.00 ➝ $23.00
5/10/2023Robert W. BairdLower Target$25.00 ➝ $20.00
3/27/2023Wells Fargo & CompanyReiterated RatingEqual Weight$11.00
3/6/2023Wells Fargo & CompanyLower TargetEqual Weight$14.00 ➝ $11.00
3/1/2023HC WainwrightReiterated RatingBuy$38.00
3/1/2023Chardan CapitalReiterated RatingBuy$29.00
3/1/2023OppenheimerLower TargetOutperform$25.00 ➝ $15.00
1/27/2023Piper SandlerUpgradeNeutral ➝ Overweight$11.00 ➝ $14.00
1/24/2023Truist FinancialBoost TargetBuy$16.00 ➝ $17.00
12/9/2022BenchmarkDowngradeNeutral$20.00 ➝ $6.00
12/8/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$20.00 ➝ $6.00
11/21/2022JMP SecuritiesLower TargetMarket Outperform$25.00 ➝ $21.00
11/20/2022Piper SandlerLower TargetNeutral$13.00 ➝ $11.00
11/18/2022Chardan CapitalLower TargetBuy$30.00 ➝ $29.00
11/18/2022OppenheimerLower Target$27.00 ➝ $25.00
11/18/2022HC WainwrightLower TargetBuy$43.00 ➝ $38.00
10/31/2022GuggenheimInitiated CoverageNeutral
9/12/2022JMP SecuritiesReiterated RatingBuy$25.00
8/23/2022Truist FinancialLower Target$18.00
8/18/2022Wells Fargo & CompanyReiterated RatingEqual Weight$14.00
8/5/2022Chardan CapitalLower Target$31.00 ➝ $30.00
8/5/2022Robert W. BairdLower TargetOutperform$34.00 ➝ $25.00
7/1/2022The Goldman Sachs GroupLower TargetBuy$64.00 ➝ $18.00
6/8/2022JMP SecuritiesReiterated RatingBuy$25.00
5/27/2022Truist FinancialLower Target$20.00
5/27/2022OppenheimerLower TargetOutperform$31.00 ➝ $27.00
5/27/2022Chardan CapitalLower TargetBuy$44.00 ➝ $31.00
5/27/2022Piper SandlerLower TargetNeutral$20.00 ➝ $13.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$79.00 ➝ $64.00
4/7/2022Truist FinancialLower Target$32.00 ➝ $29.00
4/7/2022Robert W. BairdBoost TargetOutperform$30.00 ➝ $34.00
2/28/2022Truist FinancialLower Target$45.00 ➝ $32.00
2/25/2022Chardan CapitalLower TargetBuy$50.00 ➝ $45.00
2/25/2022Robert W. BairdLower TargetOutperform$35.00 ➝ $30.00
1/28/2022Stifel NicolausUpgradeHold ➝ Buy$23.00 ➝ $25.00
1/5/2022Wells Fargo & CompanyLower Target$35.00 ➝ $25.00
12/7/2021CowenInitiated CoverageOutperform
11/15/2021OppenheimerLower TargetOutperform$38.00 ➝ $31.00
11/5/2021HC WainwrightLower TargetBuy$46.00 ➝ $43.00
11/5/2021Piper SandlerBoost TargetNeutral$18.00 ➝ $20.00
8/24/2021Robert W. BairdReiterated RatingBuy$35.00
8/11/2021JMP SecuritiesReiterated RatingBuy
7/7/2021Chardan CapitalReiterated RatingBuy
6/29/2021MizuhoInitiated CoverageBuy$30.00
6/29/2021Chardan CapitalReiterated RatingBuy$51.00
6/10/2021JMP SecuritiesUpgradeMarket Perform ➝ Outperform$32.00
5/26/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$35.00 ➝ $18.00
5/25/2021OppenheimerLower TargetOutperform$51.00 ➝ $38.00
5/20/2021Robert W. BairdLower TargetOutperform$55.00 ➝ $35.00
5/20/2021MizuhoBoost TargetBuy$30.00 ➝ $55.00
5/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$35.00 ➝ $18.00
5/19/2021Stifel NicolausDowngradeBuy ➝ Hold
5/19/2021Chardan CapitalLower TargetBuy$54.00 ➝ $51.00
5/19/2021OppenheimerLower TargetOutperform$57.00 ➝ $51.00
5/19/2021JMP SecuritiesLower TargetOutperform ➝ Market Perform$45.00 ➝ $43.00
5/19/2021BarclaysLower TargetOverweight$60.00 ➝ $40.00
5/19/2021HC WainwrightLower TargetBuy$50.00 ➝ $46.00
5/19/2021Piper SandlerLower TargetOverweight$45.00 ➝ $35.00
5/3/2021Truist FinancialInitiated CoverageBuy$50.00
4/16/2021The Goldman Sachs GroupInitiated CoverageBuy
3/8/2021HC WainwrightUpgradeNeutral ➝ Buy$50.00
3/1/2021Chardan CapitalReiterated RatingBuy
1/14/2021OppenheimerBoost TargetOutperform$43.00 ➝ $57.00
12/17/2020BarclaysBoost TargetPositive ➝ Overweight$43.00 ➝ $55.00
12/15/2020HC WainwrightDowngradeBuy ➝ Neutral
11/9/2020JMP SecuritiesBoost TargetMarket Outperform$38.00 ➝ $45.00
11/6/2020BarclaysBoost TargetOverweight$36.00 ➝ $43.00
11/6/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $45.00
10/15/2020Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$29.00 ➝ $35.00
10/6/2020Stifel NicolausLower Target$47.00 ➝ $42.00
10/6/2020BarclaysLower TargetOverweight$45.00 ➝ $36.00
10/6/2020HC WainwrightLower TargetBuy$48.00 ➝ $46.00
10/6/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$49.00 ➝ $29.00
10/6/2020OppenheimerReiterated RatingBuy$43.00
10/6/2020Chardan CapitalReiterated RatingBuy$53.00 ➝ $50.00
8/7/2020Chardan CapitalBoost TargetBuy$44.00 ➝ $53.00
8/7/2020OppenheimerReiterated RatingBuy$43.00
6/15/2020OppenheimerInitiated CoverageBuy$43.00
5/28/2020Stifel NicolausBoost TargetBuy$48.00 ➝ $50.00
5/27/2020Chardan CapitalReiterated RatingBuy
5/14/2020Chardan CapitalReiterated RatingBuy$44.00
5/6/2020Robert W. BairdBoost TargetOutperform$60.00 ➝ $65.00
5/5/2020OppenheimerInitiated CoverageBuy$43.00
5/5/2020MizuhoReiterated RatingBuy$61.00
4/29/2020HC WainwrightBoost TargetPositive ➝ Buy$36.00 ➝ $48.00
4/28/2020OppenheimerInitiated CoverageBuy$35.00 ➝ $43.00
4/27/2020Chardan CapitalBoost TargetBuy$36.00 ➝ $44.00
4/27/2020MizuhoReiterated RatingBuy$61.00
4/21/2020MizuhoInitiated CoverageBuy
(Data available from 3/14/2020 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/16/2024
  • 10 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/15/2024
  • 15 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2024
  • 11 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2024
  • 12 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/14/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
1/13/2025
  • 6 very positive mentions
  • 17 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
2/12/2025
  • 11 very positive mentions
  • 29 positive mentions
  • 12 negative mentions
  • 2 very negative mentions
Mentions as of
3/14/2025

Current Sentiment

  • 11 very positive mentions
  • 29 positive mentions
  • 12 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Iovance Biotherapeutics logo
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $3.60
Low: $3.48
High: $3.59

50 Day Range

MA: $5.55
Low: $3.52
High: $7.65

52 Week Range

Now: $3.60
Low: $3.49
High: $15.90

Volume

6,583,828 shs

Average Volume

6,970,878 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Iovance Biotherapeutics?

The following Wall Street research analysts have issued reports on Iovance Biotherapeutics in the last twelve months: Chardan Capital, HC Wainwright, JMP Securities, Piper Sandler, Robert W. Baird, StockNews.com, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for IOVA.

What is the current price target for Iovance Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for Iovance Biotherapeutics in the last year. Their average twelve-month price target is $20.25, suggesting a possible upside of 466.4%. HC Wainwright has the highest price target set, predicting IOVA will reach $32.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $6.00 for Iovance Biotherapeutics in the next year.
View the latest price targets for IOVA.

What is the current consensus analyst rating for Iovance Biotherapeutics?

Iovance Biotherapeutics currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IOVA.

What other companies compete with Iovance Biotherapeutics?

Other companies that are similar to Iovance Biotherapeutics include PTC Therapeutics, Organon & Co., ADMA Biologics, Arcellx and Zai Lab. Learn More about companies similar to Iovance Biotherapeutics.

How do I contact Iovance Biotherapeutics' investor relations team?

Iovance Biotherapeutics' physical mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company's listed phone number is (650) 260-7120 and its investor relations email address is achang@troutgroup.com. The official website for Iovance Biotherapeutics is www.iovance.com. Learn More about contacing Iovance Biotherapeutics investor relations.